CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
Research published in the American Society of Clinical Oncology shows nivolumab and nivolumab plus ipilimumab has durable response and encouraging long-term overall survivial for patients with chemotherapy-refractory esophagogastric cancer.
Read Source